Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

Feb 17 (Reuters) - Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in ...
BioSpace

Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA

Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...
Fierce Pharma

Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...
STAT

Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial

Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.
Yahoo

RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial

Add Yahoo as a preferred source to see more of our stories on Google. An RNA medicine developed by Regeneron Pharmaceuticals and Alnylam Pharmaceuticals helped control symptoms of the chronic ...

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

New Dupixent ® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in ...
Benzinga.com

FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid ...
Seeking Alpha

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination ...